Drug Repurposing During The COVID-19 Pandemic: Lessons For Expediting Drug Development And Access

Greenblatt, Wesley; Gupta, Charu; Kao, Jennifer L.

doi:10.1377/hlthaff.2022.01083

Cited by 5 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We included RCTs that satisfied the following eligibility criteria: (1) included non-hospitalised COVID-19 patients, (2) compared the use of fluvoxamine to standard of care or placebo, and (3) reported any of our outcomes of interest. Our primary efficacy outcomes include incidence of hospitalisation and incidence of healthcare utilization (which was defined as a composite incidence of emergency room visits or hospitalisation).…”

Section: Eligibility Criteria and Outcome Measuresmentioning

confidence: 99%

“…The pandemic has underscored the importance of drug repurposingwhich involves using existing medications for new therapeutic indications-as a crucial strategy for rapidly finding novel therapeutics against COVID-19. 1 Notably, drugs such as remdesivir 2 and corticosteroids 3 have been repurposed for reducing clinical deterioration and mortality among hospitalised COVID-19 patients. As COVID-19 evolves towards endemicity, the focus of drug repurposing has transitioned from inpatient management to preventing hospitalisations among outpatients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis

Deng,

Moskalyk,

Zuo

et al. 2023

Reviews in Medical Virology

View full text Add to dashboard Cite

This systematic review and meta‐analysis of randomised controlled trials (RCTs) aimed to evaluate the efficacy, safety, and tolerability of fluvoxamine for the outpatient management of COVID‐19. We conducted this review in accordance with the PRISMA 2020 guidelines. Literature searches were conducted in MEDLINE, EMBASE, International Pharmaceutical Abstracts, CINAHL, Web of Science, and CENTRAL up to 14 September 2023. Outcomes included incidence of hospitalisation, healthcare utilization (emergency room visits and/or hospitalisation), mortality, supplemental oxygen and mechanical ventilation requirements, serious adverse events (SAEs) and non‐adherence. Fluvoxamine 100 mg twice a day was associated with reductions in the risk of hospitalisation (risk ratio [RR] 0.75, 95% confidence interval [CI] 0.58–0.97; I2 = 0%) and reductions in the risk of healthcare utilization (RR 0.68, 95% CI 0.53–0.86; I2 = 0%). While no increased SAEs were observed, fluvoxamine 100 mg twice a day was associated with higher treatment non‐adherence compared to placebo (RR 1.61, 95% CI 1.22–2.14; I2 = 53%). In subgroup analyses, fluvoxamine reduced healthcare utilization in outpatients with BMI ≥30 kg/m2, but not in those with lower BMIs. While fluvoxamine offers potential benefits in reducing healthcare utilization, its efficacy may be most pronounced in high‐risk patient populations. The observed non‐adherence rates highlight the need for better patient education and counselling. Future investigations should reassess trial endpoints to include outcomes relating to post‐COVID sequelaes. Registration: This review was prospectively registered on PROSPERO (CRD42023463829).

show abstract

Section: Eligibility Criteria and Outcome Measuresmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%